Species differences in the effects of prostaglandins on inositol trisphosphate accumulation, phosphatidic acid formation, myosin light chain phosphorylation and contraction in iris sphincter of the mammalian eye: interaction with the cyclic AMP system.
Comparative studies on the effects of prostaglandins (PGs) on 1,2-diacylglycerol, measured as phosphatidic acid (PA), and inositol trisphosphate (IP3) production, cyclic AMP (cAMP) formation, myosin light chain (MLC) phosphorylation and contraction in the iris sphincter smooth muscle of rabbit, bovine and other mammalian species were undertaken and functional and biochemical relationships between the IP3-Ca++ and cAMP second messenger systems were demonstrated. The findings obtained from these studies can be summarized as follows: 1) all PGs investigated, including PGE2, PGF2 alpha, PGF2 alpha-ester, PGE1 and PGA2 increased IP3 accumulation and PA formation, and the extent of stimulation was dependent on the animal species. Thus, PGF2 alpha-ester (1 microM), the most potent of the PGs, increased IP3 accumulation in rabbit and bovine sphincters by 33 and 58%, respectively, and increased PA formation by 67 and 56%, respectively. The PG increased IP3 accumulation in both rabbit and bovine sphincters very rapidly (T1/2 values about 26 sec) and in a dose-dependent manner. 2) The PG had no effect on MLC phosphorylation in the rabbit sphincter, but it increased that of the bovine by 36%. 3) The PG increased cAMP formation by 75% in the rabbit sphincter but it had no effect on that of the bovine. 4) The PG induced a maximal contractile response in the bovine sphincter but it had no effect on that of the rabbit. 5) In the bovine, PGA2 induced IP3 accumulation and contraction, without an effect on cAMP formation; however, in the rabbit, cat and dog it increased cAMP formation and had no effect on IP3 accumulation and contraction.(ABSTRACT TRUNCATED AT 250 WORDS)
Yousufzai
S Y
SY
Department of Cell and Molecular Biology, Medical College of Georgia, Augusta.
Chen
A L
AL
Abdel-Latif
A A
AA
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002217:Carbachol / Q000494:pharmacology; D002415:Cats; D002417:Cattle; D000242:Cyclic AMP / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D015544:Inositol 1,4,5-Trisphosphate; D007295:Inositol Phosphates / Q000378:metabolism*; D007498:Iris / Q000187:drug effects* / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects*; D009218:Myosins / Q000378:metabolism*; D010712:Phosphatidic Acids / Q000096:biosynthesis*; D010766:Phosphorylation; D011224:Prazosin / Q000494:pharmacology; D011453:Prostaglandins / Q000378:metabolism / Q000494:pharmacology*; D011817:Rabbits; D013045:Species Specificity; D013373:Substance P / Q000037:antagonists & inhibitors; D013403:Sugar Phosphates / Q000378:metabolism*; D013552:Swine
D007295:Inositol Phosphates; D010712:Phosphatidic Acids; D011453:Prostaglandins; D013403:Sugar Phosphates; D013373:Substance P; D001285:Atropine; D015544:Inositol 1,4,5-Trisphosphate; D002217:Carbachol; D000242:Cyclic AMP; D009218:Myosins; D002118:Calcium; D011224:Prazosin